I'm LongbridgeAI, I can summarize articles.Popular Pre-Market Trades in U.S. Stocks
Best Buy's stock price fell 7.39% in pre-market trading, possibly related to recent tariff policies. Recently, U.S. President Trump implemented reciprocal tariff policies against major home appliance manufacturing countries, including China, Vietnam, and Thailand. According to a report by Jefferies analysts, this could lead retailers to increase platform fees by 30%. For retail giants like Best Buy, this will increase operating costs and may lead to a decline in profitability in the U.S. market. Additionally, this policy could have a negative impact on the overall economy, increasing operational risks and cost pressures for businesses.
Sumitomo Mitsui Financial Group's stock fell 7.12% in pre-market trading, possibly due to market concerns triggered by news of its collaboration with U.S. companies to develop a stablecoin pegged to fiat currency.
According to a report by Nikkei, Sumitomo Mitsui Financial Group plans to collaborate with Ava Labs and Fireblocks to launch a stablecoin and develop infrastructure together with local IT company TIS. This project is planned to conduct empirical experiments in the second half of the fiscal year 2025 and may be further advanced in fiscal year 2026.
Although this collaboration may bring new business opportunities to Sumitomo Mitsui Financial Group, the market may be cautious about its investment risks in the cryptocurrency sector, especially against the backdrop of increasingly stringent cryptocurrency regulations in the global financial market.
Furthermore, the success of the stablecoin project depends on the improvement of technology, regulation, and market infrastructure, and these uncertainties may lead investors to worry about Sumitomo Mitsui Financial Group's short-term stock performance.
Top Gainers in Pre-Market U.S. Stocks
Protagenic Therapeutics' stock price surged 156.87% in pre-market trading, possibly related to its recent SEC filing disclosures. The company detailed its market risks and growth management strategies in the 10-K filing submitted on March 31, which may have enhanced investor confidence in its future development. Additionally, the overall positive trend in the biopharmaceutical industry may have also driven the stock's rise. Investors may hold an optimistic view of the company's innovation capabilities and market potential in the biotechnology sector, leading to a significant increase in stock price